Clonidine extended-release tablets for the treatment of ADHD

Joan Daughton; Lindsey Corr; Howard Liu; Madeline West

doi:10.2217/npy.12.7

Clonidine extended-release tablets for the treatment of ADHD

Joan Daughton, Lindsey Corr, Howard Liu, Madeline West

Research output: Contribution to journal › Review article › peer-review

Abstract

Treatment guidelines for ADHD recommend stimulants as a first-line therapy. However, as many as 15% of patients are unresponsive to these medications, while others are unable to tolerate stimulants. For some patients with ADHD, there is a clear need for nonstimulant therapies. This article aims to summarize the current evidence regarding the use of clonidine extended release (Kapvay™, Shionogi Pharma, GA, USA) in the treatment of children and adolescents with ADHD.

Original language	English (US)
Pages (from-to)	117-123
Number of pages	7
Journal	Neuropsychiatry
Volume	2
Issue number	2
DOIs	https://doi.org/10.2217/npy.12.7
State	Published - Apr 2012

ASJC Scopus subject areas

Clinical Neurology
Psychiatry and Mental health

Access to Document

10.2217/npy.12.7

Cite this

@article{76531b95ea54453389e8a1bc8d1999f7,

title = "Clonidine extended-release tablets for the treatment of ADHD",

abstract = "Treatment guidelines for ADHD recommend stimulants as a first-line therapy. However, as many as 15% of patients are unresponsive to these medications, while others are unable to tolerate stimulants. For some patients with ADHD, there is a clear need for nonstimulant therapies. This article aims to summarize the current evidence regarding the use of clonidine extended release (Kapvay{\texttrademark}, Shionogi Pharma, GA, USA) in the treatment of children and adolescents with ADHD.",

author = "Joan Daughton and Lindsey Corr and Howard Liu and Madeline West",

year = "2012",

month = apr,

doi = "10.2217/npy.12.7",

language = "English (US)",

volume = "2",

pages = "117--123",

journal = "Neuropsychiatry",

issn = "1758-2008",

publisher = "University of Virginia",

number = "2",

}

TY - JOUR

T1 - Clonidine extended-release tablets for the treatment of ADHD

AU - Daughton, Joan

AU - Corr, Lindsey

AU - Liu, Howard

AU - West, Madeline

PY - 2012/4

Y1 - 2012/4

N2 - Treatment guidelines for ADHD recommend stimulants as a first-line therapy. However, as many as 15% of patients are unresponsive to these medications, while others are unable to tolerate stimulants. For some patients with ADHD, there is a clear need for nonstimulant therapies. This article aims to summarize the current evidence regarding the use of clonidine extended release (Kapvay™, Shionogi Pharma, GA, USA) in the treatment of children and adolescents with ADHD.

AB - Treatment guidelines for ADHD recommend stimulants as a first-line therapy. However, as many as 15% of patients are unresponsive to these medications, while others are unable to tolerate stimulants. For some patients with ADHD, there is a clear need for nonstimulant therapies. This article aims to summarize the current evidence regarding the use of clonidine extended release (Kapvay™, Shionogi Pharma, GA, USA) in the treatment of children and adolescents with ADHD.

UR - http://www.scopus.com/inward/record.url?scp=84876509084&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876509084&partnerID=8YFLogxK

U2 - 10.2217/npy.12.7

DO - 10.2217/npy.12.7

M3 - Review article

AN - SCOPUS:84876509084

SN - 1758-2008

VL - 2

SP - 117

EP - 123

JO - Neuropsychiatry

JF - Neuropsychiatry

IS - 2

ER -

Clonidine extended-release tablets for the treatment of ADHD

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this